The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
The agreement covers the manufacture and supply of superparamagnetic particles. T2 Bio will be a non-exclusive reseller of the particles as part of its products.
The deal between GE, the Global Good Fund, and Access Bio is to manufacture and distribute malaria diagnostic technologies in low-resource nations.